Association of Irisin Hormone With Some Physiological And Inflammatory Parameters in Patients With Type 2 Diabetic Mellitus (T2DM) in Thi-Qar Province/ Iraq


  • Saad H. Al-Badry 1, 2Biology Department, College of Science, University of Thi-Qar
  • Khalid G. Al-Fartoosi 1, 2Biology Department, College of Science, University of Thi-Qar


Irisin, T2DM, inflammatory parameters.


The present study aimed to assessment of irisin level in patients with the newly onset type 2 "diabetes mellitus" (T2D.M.) and the scanning the association of irisin value with some physiological and inflammatory parameters. This study comprised 60 individuals diagnosed in newly onset T2D.M. and 40 healthy contributors (control group). IL-6 and C-reactive protein(CRP) concentration was calculated in patient who involved in this study. Serum irisin levels in addition to inflammatory factors were evaluated by ELISA kit.
The present study showed a significant increasing (P ≤ 0.05) of glycohemoglobin (HbA1C) and FBS level in patient with DM2 compared with the control groups (6.88 ± 1.02 vs 4.15±0.56; 7.85 ± 1.89 vs 4.94 ± 0.40) respectively. Also, the results explained a significant increased (P ≤ 0.05) of T-Ch, Tg and LDL level in DM2 group compared with the control group (4.27±0.90 vs 4.23± 0.40; 2.14 ± 0.86 vs 1.89 ± 0.26; 2.84 ± 0.94 vs 2.23 ± 0.52) respectively. Whereas, the results showed a significant decrease (P ≤ 0.05) of irisin, insulin, C-peptide and HLD in DM2 group compared with the control group (22.32 ± 4.55 vs 27.81 ± 2.93; 18.29 ± 3.66 vs 27.27 ± 6.90; 3.12 ± 0.99 vs 6.03 ± 0.48; 1.0 ± 0.17 vs 1.61±0.37) respectively. On the other hand, the results of inflammatory parameters showed a significant increase (P ≤ 0.05) of IL-6 and CRP level compared with the control group (19.85 ± 4.97 vs 12.0 ± 1.23; 8.41 ± 2.11 vs 4.60 ± 0.35) respectively.
In correlation analysis the results showed a negative association between irisin and (HbA1c) (r= -0.152), glucose (r= -0.331), insulin (r= -0.156), HDL (r= -0.114) and BMI (r= -0.219). Whereas, the results showed positive correlation between irisin and IL-6 (r=0. 0.115), CRP (r= 0.153), C-peptide (r=0.013), T-Ch (r= 0.057), Tg (r=0.209) and LDL(r=0.035).


Allian, C.C.; Poon, L.S.; Chan, C.S.; Richmond, W. and FU, P.C. (1974) “Enzymatic Determination of Total Serum Cholesterol.” Clinical Chem. 20, (4): 470–75. 2. Arias-Loste, M. T., Ranchal, I., Romero-Gómez, M., and Crespo, J. (2014). Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. International journal of molecular sciences, 15(12), 23163-23178.

Assyov Y., Gateva A., Tsakova A., Kamenov Z. (2016). Irisin in glucose continuum. Exp. Clin. Endocrinol. Diabetes; 124: 22–27. 4. Aydin, S. (2014). Three new players in energy regulation: preptin, adropin and irisin. Peptides, 56, 94-110. 5. Azadbakht, L., Kimiagar, M., Mehrabi, Y., Esmaillzadeh, A., Hu, F. B., & Willett, W. C. (2007). Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes care, 30(4), 967-973. 6. Badimon, J. J., Badimon, L., & Fuster, V. (1990). Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. The Journal of clinical investigation, 85(4), 1234-1241. 7. Bains, S., Anyaeche, C., Wyatt, A., Coker, O., & Bolodeoku, J. (2017). Evaluation of Point of Care Test (POCT), i-CHROMA™ Serum C-Reactive Protein (CRP) Assay and Microalbumin Urine (MAU) Methods. Annals of Clinical and Laboratory Research, 5(3), 192. 8. Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., and Kajimura, S. (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463-8.

Choi, Y. K., Kim, M. K., Bae, K. H., Seo, H. A., Jeong, J. Y., Lee, W. K., and Park, K. G. (2013). Serum irisin levels in new-onset type 2diabetes. Diabetes research and clinical practice, 100(1), 96-101.

Ebert, T., Focke, D., Petroff, D., Wurst, U., Richter, J., Bachmann, A., and Bast, I. (2014). Serum levels of the myokine irisin in relation to metabolic and renal function. European journal of endocrinology, 170(4), 501-506. 11. Endocrinologica, M. (2017). Irisin as a regulator of bone and glucose metabolism: a narrative review. Minerva endocrinologica.

Espes, D., Lau, J., and Carlsson, P. O. (2015). Increased levels of irisin in people with long‐standing Type 1 diabetes. Diabetic medicine, 32(9), 1172-1176. 13. Febbraio, M. A. (2007). Exercise and inflammation. 14. Forouhi, N. G., & Wareham, N. J. (2014). Epidemiology of diabetes. Medicine (Abingdon). 42 (12): 698–702.

Fukushima, Y., Kurose, S., Shinno, H., Cao Thi Thu, H., Tamanoi, A., Tsutsumi, H., and Kimura, Y. (2016). Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. Obesity science & practice, 2(2), 203-209. 16. Harris, M. I. (1998). Diabetes in America: epidemiology and scope of the problem. Diabetes care, 21(Supplement 3), C11-C14. 17. Hope, S. V., Knight, B. A., Shields, B. M., Strain, W. D., Hattersley, A. T., Choudhary, P., and Jones, A. G. (2016). Low c-peptide is associated with high glycaemic variability and hypoglycaemia in insulin-treated patients with type 2 diabetes. Diabet Med, 33, 144. 18. Jeppsson, J. O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., ... & Thienpont, L. (2002). Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical chemistry and laboratory medicine, 40(1), 78-89. 19. Jones, A. G., and Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817. 20. Kamran M. A. (2010). Association between high risk foot, retinopathy and hba1c in saudi diabetic population. Pak J Physiol., 622-28. 21. Kramer, C. K., Choi, H., Zinman, B., and Retnakaran, R. (2014). Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care, DC_132591.

Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold III, P., Burger, D and Faustman, D. L. (2015). Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabetic Medicine, 32(10), 1346-1353.

Lachin, J. M., McGee, P., Palmer, J. P., and DCCT/EDIC research group. (2014). Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes, 63(2), 739-748. 24. Leighton, E., Sainsbury, C. A., and Jones, G. C. (2017). A practical review of C-peptide testing in diabetes. Diabetes therapy, 8(3), 475-487.

Liu, J. J., Wong, M. D., Toy, W. C., Tan, C. S., Liu, S., Ng, X. W., .and Lim, S. C. (2013). Lower circulating irisin is associated with type 2 diabetes mellitus. Journal of Diabetes and its Complications, 27(4), 365-369.

Miyazawa, H., Bannai, H., Yanase, T., Morita, C., Satoh, S., Sugiyama, J., ... & Inouye, S. (1999). A reverse-sandwich enzyme-linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera. Clin. Diagn. Lab. Immunol., 6(5), 701-704. 27. Moreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., and Fernández-Real, J. M. (2013). Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. The Journal of Clinical Endocrinology & Metabolism, 98(4), E769-E778.

Nuttall, F. Q. (2015). Body mass index: obesity, BMI, and health: a critical review. Nutrition today, 50(3), 11.

Pedersen, B. K., Steensberg, A., Fischer, C., Keller, C., Keller, P., Plomgaard, P., and Saltin, B. (2003). Searching for the exercise factor: is IL-6 a candidate? Journal of Muscle Research & Cell Motility, 24(2-3), 113. 30. Peter O. and Kwiterovich, Jr., M.D. (2004). Diagnostics, R., & Diagnostics, B. M. Laboratory Procedure Manual. Laboratory Procedure Manual, 410-614-1030. 31. Rustemeijer, C.; Schouten, J. A.; Janssen, E. N.; Spooren, P. F. and Van Doormaal, J. J. (1997). Pravastatin in diabetes associated hypercholesterolemia. Acta. diabetol., 34(4): 294-300. 32. Sanchis-Gomar, F., & Perez-Quilis, C. (2014). The p38–PGC-1α–irisin–betatrophin axis: Exploring new pathways in insulin resistance. Adipocyte, 3(1), 67-68.

Sanchis-Gomar, F., Lippi, G., Mayero, S., Perez‐Quilis, C., & García‐Giménez, J. L. (2012). Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. Journal of diabetes, 4(3), 196-196. 34. Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes dyslipidemia. Diabetes Therapy, 7(2), 203-219.

Trinder, P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Annals of clinical Biochemistry, 6(1), 24-27. 36. Vaziri, N. D.; Sato, T. and Liang, K. (2003). Molecular mechanism of expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. hypercholesterolemia. Acta. diabetol., 34(4): 294-300. 37. World Health Organization. (2016). World health statistics 2016: monitoring health for the SDGs sustainable development goals. World Health. Organization. 38. Xiong, X. Q., Chen, D., Sun, H. J., Ding, L., Wang, J. J., Chen, Q., and Gao, X. Y. (2015). FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1852(9), 1867-1875.

Yan, B.; Shi, X.; Zhang, H.; Pan, L. and Ma, Z. et al. (2014). Association of Serum Irisin with Metabolic Syndrome in Obese Chinese Adults. PLoS ONE., 9(4). 40. Zhang, C., Ding, Z., Lv, G., Li, J., Zhou, P., & Zhang, J. (2016). Lower irisin level in patients with type 2 diabetes mellitus: A case‐control study and meta analysis meta. Journal of diabetes, 8(1), 56-62.

Zhang, M., Chen, P., Chen, S., Sun, Q., Zeng, Q. C., Chen, J. Y., and Wang, J. K. (2014). The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci, 18(11), 1567-72.